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Introduction
There is a dire need of non-invasive biomarkers of
lupus nephritis (LN) activity. MicroRNAs (miRNAs)
are endogenous, non-coding, single-stranded RNAs
involved in the regulation of host genome expression
at the post-transcriptional level. Previous miRNA
expression profiling studies have generated some
unique miRNA signatures (including miR-125a,
miR-127, miR-146a,miR-150,miR-155) that are asso-
ciated with systemic lupus erythematosus (SLE), but
their role as biomarkers of LN has not been well
examined.
Objectives
To determine levels of candidate miRNA biomarkers in
blood and urine to the assess the differences in children
with active LN vs. extrarenal SLE vs. controls. Also to
assess potential associations with the LN-Panel [NGAL,
MCP1, transferrin (Tf), Cystatin C, Beta-trace protein]
of novel urinary biomarkers and traditional LN biomarkers
(GFR, protein: creatinine ratio); and to explore combina-
tions of biomarkers to predict LN activity using stepwise
regression modeling.
Methods
In this ongoing research study, miRNA was measured
using rtPCR in the urine pellet (UP) and supernatant (sup)
as well as blood in patients with JIA and fibromyalgia
serving as disease controls and 14 patients with active LN
and 10 with extrarenal SLE every 6 months. Disease
activity was measured by the SLEDAI. Urine samples were
assayed for the LN-Panel and traditional biomarkers were
recorded.
Results
LN activity measured by the SLEDAI was strongly posi-
tively correlated with sup levels of miR-125a (r > 0.7),
moderately with miR-127, miR-150, miR-155 (r> 0.5), and
moderately with miR-146a in blood cells. In the sup,
miRNA-125a was significantly higher with active vs. not
active LN (WSR test; p= 0.018) and was moderately asso-
ciated with all LN-Panel markers (r = 0.53 – 0.66).
Exploratory regression modeling suggests that NGAL,
MCP1, TF and miR-125a in the sup are relevant
combinatorial LN biomarkers (all standardized beta
coefficients > |0.3| and p < 0.01) to predict LN activity
(renal SLEDAI) at high accuracy (R-square = 87%).
Similar results were found when the renal BILAG or
SLICC Renal Activity Score were used to measure LN
activity instead of the renal SLEDAI.
Conclusion
The miRNAs miR-125a, miR-127, miR-146a,miR-150,
miR-155 are differentially excreted in the urine with
active LN. Based on initial evaluations these miRNA
complement newer LN biomarkers (NGAL, MCP, TF)
in their ability to assess concurrent LN activity.
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